Test Price
2,800 AED✅ Home Collection Available
MITF Gene Melanoma Susceptibility – Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين MITF للاستعداد للإصابة بسرطان الجلد الميلانيني في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
الملخص التنفيذي (Executive Summary)
يوفر هذا التحليل الجيني المتقدم تسلسل الجينوم الكامل لجين MITF بأحدث تقنيات الجيل التالي (NGS) في مختبر معتمد آيزو 9001:2015، مع ضمان دقة تشخيصية بنسبة 99.9% وخدمة سحب منزلي معتمد. نلتزم بأعلى معايير هيئة الصحة بدبي والقانون الاتحادي رقم 41 لسنة 2024 لحماية البيانات الجينية.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in Result Interpretation included.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
UAE Regulatory Compliance & Accreditation
Licensed Facility No. 9834453. ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139). Full adherence to Federal Decree-Law No. 41 of 2024 (Art. 87) on medical liability, Child Data Safety Law 2026 for minors, and UAE PDPL for genetic data privacy. Your results are handled by DHA-certified clinical geneticists.
In-Depth Genetic Insight for Melanoma Risk
يُحدد تحليل جين MITF الطفرات الوراثية المرتبطة بسرطان الجلد الميلانيني العائلي، مما يتيح استراتيجيات وقائية وعلاجية مخصصة. This comprehensive NGS‑based test sequences the entire MITF gene to identify pathogenic variants linked to cutaneous malignant melanoma susceptibility, empowering you and your physician with actionable genetic data.
| Feature | Our MITF NGS Test | Common Targeted Panel (Alternative) |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) – Full Gene | Sanger Sequencing / Limited Panels |
| Coverage | Complete coding region + splice sites | Selected hot‑spots only |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks (often) |
| Price | 2800 AED | 2500–3500 AED (variable) |
Physician Insight & Safety Protocol
Note from Dr. PRABHAKAR REDDY, DHA-licensed Consultant (DHA Lic No: 61713011):
“Genetic testing for melanoma risk is a powerful tool, but it’s only one piece of your health puzzle. A positive MITF variant does not guarantee cancer; it signifies an increased susceptibility that, when combined with regular skin checks and sun-protective behaviors, can be managed effectively. I urge you to discuss your results with a clinical geneticist or oncologist for a personalized prevention plan.”
⚠️ Important Medication Warning:
Do not discontinue prescribed medication without consulting your doctor. This test is a genetic susceptibility analysis; it does not replace ongoing treatment or surveillance.
🚨 Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Not intended for minors without legal guardian consent and DHA‑mandated genetic counselling (CDS Law 2026).
- Exclusion: Not suitable as a stand‑alone diagnostic test for acute melanoma; it assesses inherited risk only.
- Emergency Red Flags: New, changing, or bleeding moles; sudden vision changes; severe unexplained pain—seek immediate medical attention (call 998 for UAE ambulance).
- ER Condition: If you experience a rapidly growing skin lesion, do not delay; visit the nearest emergency department.
Patient FAQ & Clinical Guidance
1. What does the MITF gene melanoma test tell me?
Snippet: It identifies inherited mutations in the MITF gene that significantly raise your lifetime risk of developing cutaneous malignant melanoma.
The test uses next‑generation sequencing to detect pathogenic variants; results are classified as positive, negative, or variant of uncertain significance (VUS). A positive finding means you carry a known risk allele, enabling early surveillance and preventive strategies.
ما الذي يخبرني به تحليل جين MITF لسرطان الجلد الميلانيني؟
الجواب المقتضب: يحدد الطفرات الموروثة في جين MITF التي ترفع بشكل كبير خطر إصابتك بسرطان الجلد الميلانيني الجلدي الخبيث مدى الحياة.
يستخدم التحليل تسلسل الجيل التالي للكشف عن المتغيرات المسببة للأمراض؛ وتصنف النتائج على أنها إيجابية، سلبية، أو متغير غير مؤكد الأهمية (VUS). النتيجة الإيجابية تعني حملك لأليل خطر معروف، مما يتيح المراقبة المبكرة والاستراتيجيات الوقائية.
2. How is the sample collected and what is the preparation?
Snippet: A simple blood draw or a one‑drop finger‑prick on an FTA card is all that’s needed, with no fasting required.
Our DHA‑certified phlebotomists perform home collection using a cold‑chain kit. Prior to the test, you should provide a detailed family history of melanoma or other cancers. A pre‑test genetic counselling session (included) will chart your pedigree to ensure accurate interpretation.
3. Can this test predict if I will get melanoma?
Snippet: No test can predict with certainty; it stratifies your genetic risk to guide personalized prevention, not destiny.
Even with a high‑risk MITF variant, most carriers never develop melanoma if they follow sun safety and regular dermatological exams. This is a susceptibility, not a diagnostic or prognostic tool for existing cancer.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians